Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Cantech Holding's Total Liabilities for the quarter that ended in Sep. 2015 was $0.87 Mil. Cantech Holding's Total Assets for the quarter that ended in Sep. 2015 was $0.01 Mil.
Therefore, Cantech Holding's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2015 was 79.36.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Cantech Holding Liabilities-to-Assets Related Terms
Cantech Holding Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Cantech Holding's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSSP vs HSTC, NTRR, TLOG: Liabilities-to-Assets Comparison
For the Biotechnology subindustry, Cantech Holding's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cantech Holding Liabilities-to-Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cantech Holding's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Cantech Holding's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Cantech Holding's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2014 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cantech Holding (BSSP) has a Liabilities-to-Assets of 79.36 as of Sep. 2015. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Cantech Holding and its competitors.
Is Cantech Holding's Liabilities-to-Assets too high?
Cantech Holding's current Liabilities-to-Assets is 79.36.
How does Cantech Holding's Liabilities-to-Assets compare to HSTC and NTRR?
Cantech Holding's Liabilities-to-Assets of 79.36 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Cantech Holding and its competitors. Cantech Holding's current Liabilities-to-Assets is 79.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantech Holding stock overvalued right now?
Cantech Holding (BSSP) has a current Liabilities-to-Assets of 79.36. The current Liabilities-to-Assets is 79.36. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Cantech Holding (BSSP), the current Liabilities-to-Assets is 79.36 as of Sep. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cantech Holding Inc is a development stage immunotherapeutic-based technology company. Principally, it is focused on commercialization of its proprietary proteins for the treatment of cancer and various infectious diseases. Its Irreversible Pepsine Fraction (IPF) is a therapeutic platform technology that can be used to facilitate varieties of applications. The company's product consists of IMMUNE-THERAPEUTIC PROTEIN which is a therapeutic protein isolated from porsine pepsin and is irreversible, modified, and fractionated to the sequence IPF.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSSP has been successfully added to your 
